Sangamo Therapeutics

Sangamo Therapeutics is a biotechnology company that develops genomic medicines using proprietary platform technologies such as zinc finger nucleases and CRISPR‑based gene editing to treat genetic diseases. The company focuses on both in vivo and ex vivo approaches, targeting disorders including hemophilia, Huntington’s disease, and various lysosomal storage disorders. Through its research programs, Sangamo aims to correct disease‑causing mutations at the DNA level, offering the potential for durable therapeutic effects. It also collaborates with larger pharmaceutical firms to advance candidates into clinical trials and eventual commercialization.

Sangamo Therapeutics is headquartered in Richmond, California, United States, and is publicly traded on the NASDAQ under the ticker symbol SGMO. The company maintains research and development facilities in the United States and has established a network of collaborations with academic institutions and industry partners. These relationships give it a notable footprint in the rapidly evolving gene therapy and genome editing sectors.

A distinguishing attribute of Sangamo is its pioneering work with zinc finger nucleases, which were among the first engineered nucleases enabling precise genome editing and formed the foundation of its early intellectual property. The company has expanded its technology base to include other gene editing modalities and delivery systems, building a broad patent portfolio that supports its therapeutic programs. This specialization in precision genomic medicine sets it apart from many peers that focus on broader biologics or small‑molecule approaches.

Sangamo Therapeutics operates as an independent publicly traded company, with ownership dispersed among public shareholders and no single parent entity. It pursues its mission through internal research programs and external partnerships, adapting its organizational structure to support both early‑stage discovery and later‑stage clinical development.